The novel use of bevacizumab and photodynamic therapy in the treatment of best disease.

Abstract

PURPOSE:

To report on the novel use of bevacizumab (Avastin) in combination with photodynamic therapy (PDT) for the treatment of Best disease with choroidal neovascularization.

METHODS:

A 17-year-old girl with Best disease, choroidal neovascularization, and subretinal hemorrhage in the right eye was treated with bevacizumab and PDT.

RESULTS:

The use of bevacizumab and PDT was associated with a change in vision from counting fingers to 20/25 and was well tolerated by the patient.

CONCLUSION:

The use of bevacizumab and PDT in the management of Best disease seems to be a very effective method of treatment showing improvement in visual acuity.This is the first case to be reported in the literature of bevacizumab in combination with PDT for the treatment of choroidal neovascularization in Best disease.

• Authors: Elliott Brodbaker, Rani Al Karmi, Bernard Hurley, Stuart G Coupland
• Journal: Retinal cases & brief reports (Retin Cases Brief Rep) Vol. 4 Issue 2 Pg. 194-7 ( 2010) ISSN: 1935-1089 [Print] United States
• PMID: 25390401 (Publication Type: Journal Article)